WolverHeme Happy Hour

Bernard Marini, Anthony Perissinotti, et al.
  • 0.0 (0)
  • MEDICINE
  • MONTHLY
WolverHeme Happy Hour

Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.

  1. 16 NOV

    A Bunch of ASHholes Discuss Myeloma Abstracts

    In this episode, Anthony and Bernie are joined by Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin to discuss the most intriguing ASH 2024 abstracts! Should any of the research from ASH 2024 change your practice? Find out!

    56 min

  2. 8 NOV

    Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

    In this episode, Bernie and Anthony are joined by two special guest expert hematologists: Dr. David Russler-Germain Dr. Tycel Phillips We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired? Stay tuned to find out!

    48 min

  3. 10 OCT

    Episode 27: Mantle Cell Masterclass with Tycel Phillips

    In this episode, Tycel Phillips, MD joins Anthony and Bernie to discuss updates in Mantle Cell Lymphoma, including the TRIANGLE study and the recently published results of glofitamab in R/R MCL. TRIANGLE: https://pubmed.ncbi.nlm.nih.gov/38705160/ Glofitamab: https://pubmed.ncbi.nlm.nih.gov/39365960/

    1h 1m

  4. 28 AUG

    Houston, we don't have a problem... with APOLLO

    In this episode, Anthony and Bernie discuss the recently reported APOLLO trial in high-risk APL and debate whether this should represent the new standard of care in this population. We also review key practical considerations for the treatment of APL patients, including side effect management and treatment of APL in unique clinical scenarios. APOLLO: https://library.ehaweb.org/eha/2024/eha2024-congress/422206/uwe.platzbecker.first.results.of.the.apollo.trial.a.randomized.phase.iii.study.html

    59 min

  5. 13 JUN

    From Ancient Remedies to Modern Miracles: The Evolution of APL Treatment

    In this episode, Bernie and Anthony review the full history of APL treatment, in preparation for the upcoming plenary presentation of the APOLLO study THIS WEEKEND at EHA 2024! How did we get to our current standard of care in APL? How and why did the PETHEMA, GIMEMA, UK MRC, and other cooperative group regimens evolve over time into what they are today? And importantly, is the APOLLO control arm (no arsenic!), ok? Tune in to find out!

    58 min

  6. 17 APR

    Episode 24: Myeloma Madness with the Myeloma Man

    In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma.

    59 min

  7. 25 JAN

    Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion

    In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL! Abstracts discussed: https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions) https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R T-ALL https://ash.confex.com/ash/2023/webprogram/Paper187694.html - Cal-PEG is toxic https://ash.confex.com/ash/2023/webprogram/Paper188064.html - Ponatinib + Blinatumomab https://ash.confex.com/ash/2023/webprogram/Paper187773.html - D-ALBA (Dasatinib + Blinatumomab) https://ash.confex.com/ash/2023/webprogram/Paper189632.html - GIMEMA (Dasatinib or Ponatinib + Blinatumomab)

    58 min

  8. 29/12/2023

    LymphOMG: Pouring Over Lymphoma Abstracts from ASH

    OMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion! Abstracts Discussed! SYMPATICO (Ibrutinib + Ven in R/R MCL): https://ash.confex.com/ash/2023/webprogram/Paper191921.html Nivo-AVD in elderly Hodgkin Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper180114.html BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL: https://ash.confex.com/ash/2023/webprogram/Paper180069.html CAR-T in CNS Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper174883.html (EBMT data), https://ash.confex.com/ash/2023/webprogram/Paper184345.html (Multicenter retrospective study) Synthetic Control Arms: https://ash.confex.com/ash/2023/webprogram/Paper177708.html POLARIX Subgroup Analysis (shout out to the Blood Cancer Talks crew!): https://x.com/Eddie_Cliff/status/1733901400822993257?s=20

    1h 13m
See All (30)

About

Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.

Information

  • Creator
    Bernard Marini, Anthony Perissinotti, et al.
  • Years Active
    2022 - 2024
  • Episodes
    30
  • Rating
    Explicit
  • Copyright
    © Bernard Marini, Anthony Perissinotti, et al.
  • Show Website
    WolverHeme Happy Hour

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada